396 related articles for article (PubMed ID: 26203127)
1. High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome.
Casina VC; Hu W; Mao JH; Lu RN; Hanby HA; Pickens B; Kan ZY; Lim WK; Mayne L; Ostertag EM; Kacir S; Siegel DL; Englander SW; Zheng XL
Proc Natl Acad Sci U S A; 2015 Aug; 112(31):9620-5. PubMed ID: 26203127
[TBL] [Abstract][Full Text] [Related]
2. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
Yamaguchi Y; Moriki T; Igari A; Nakagawa T; Wada H; Matsumoto M; Fujimura Y; Murata M
Thromb Res; 2011 Aug; 128(2):169-73. PubMed ID: 21496883
[TBL] [Abstract][Full Text] [Related]
3. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K
Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428
[TBL] [Abstract][Full Text] [Related]
4. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
Jian C; Xiao J; Gong L; Skipwith CG; Jin SY; Kwaan HC; Zheng XL
Blood; 2012 Apr; 119(16):3836-43. PubMed ID: 22289888
[TBL] [Abstract][Full Text] [Related]
5. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF.
Pos W; Crawley JT; Fijnheer R; Voorberg J; Lane DA; Luken BM
Blood; 2010 Feb; 115(8):1640-9. PubMed ID: 20032502
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura.
Halkidis K; Meng C; Liu S; Mayne L; Siegel DL; Zheng XL
Blood; 2023 Jun; 141(24):2993-3005. PubMed ID: 37023370
[TBL] [Abstract][Full Text] [Related]
7. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
Thomas MR; de Groot R; Scully MA; Crawley JT
EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
[TBL] [Abstract][Full Text] [Related]
8. [anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura].
Matsumoto M
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(2):95-103. PubMed ID: 23629429
[TBL] [Abstract][Full Text] [Related]
9. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura.
Luken BM; Turenhout EA; Hulstein JJ; Van Mourik JA; Fijnheer R; Voorberg J
Thromb Haemost; 2005 Feb; 93(2):267-74. PubMed ID: 15711742
[TBL] [Abstract][Full Text] [Related]
10. Conformational activation of ADAMTS13.
South K; Luken BM; Crawley JT; Phillips R; Thomas M; Collins RF; Deforche L; Vanhoorelbeke K; Lane DA
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18578-83. PubMed ID: 25512499
[TBL] [Abstract][Full Text] [Related]
11. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.
Kremer Hovinga JA; Lämmle B
Hematology Am Soc Hematol Educ Program; 2012; 2012():610-6. PubMed ID: 23233642
[TBL] [Abstract][Full Text] [Related]
12. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
[TBL] [Abstract][Full Text] [Related]
13. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
Kato S; Fujimura Y
Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
[TBL] [Abstract][Full Text] [Related]
14. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura.
Luken BM; Kaijen PH; Turenhout EA; Kremer Hovinga JA; van Mourik JA; Fijnheer R; Voorberg J
J Thromb Haemost; 2006 Nov; 4(11):2355-64. PubMed ID: 16898953
[TBL] [Abstract][Full Text] [Related]
15. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP.
Luken BM; Turenhout EA; Kaijen PH; Greuter MJ; Pos W; van Mourik JA; Fijnheer R; Voorberg J
Thromb Haemost; 2006 Sep; 96(3):295-301. PubMed ID: 16953270
[TBL] [Abstract][Full Text] [Related]
16. ADAMTS13 and von Willebrand factor interactions.
Zander CB; Cao W; Zheng XL
Curr Opin Hematol; 2015 Sep; 22(5):452-9. PubMed ID: 26186678
[TBL] [Abstract][Full Text] [Related]
17. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies.
Crawley JT; Scully MA
Hematology Am Soc Hematol Educ Program; 2013; 2013():292-9. PubMed ID: 24319194
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
19. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
Starke R; Machin S; Scully M; Purdy G; Mackie I
Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414
[TBL] [Abstract][Full Text] [Related]
20. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
